Vortioxetine, a novel antidepressant for the treatment of major depressive disorder (MDD), is
a 5-HT 3, 5-HT 7 and 5-HT 1D receptor antagonist, 5-HT 1B receptor partial agonist, 5-HT …

The efficacy and safety of vortioxetine, an antidepressant approved for the treatment of
adults with major depressive disorder (MDD), was studied in 11 randomized, double-blind …

Background Valid assessment of drug efficacy and safety requires an evidence base free of
reporting bias. Using trial reports in Food and Drug Administration (FDA) drug approval …

The safety and tolerability of vortioxetine in adults with major depressive disorder was
assessed. Tolerability was based on the nature, incidence and severity of treatment …

This study assessed the efficacy, tolerability and safety of vortioxetine versus placebo in
adults with recurrent major depressive disorder. This double-blind, randomized, placebo …

Introduction: Vortioxetine is a novel antidepressant drug approved for the treatment of major
depressive disorder (MDD) in adults. It is formulated into tablets and has a dose range of 5 …

Monoamine-based treatments for depression have evolved greatly over the past several
years, but shortcomings such as suboptimal efficacy, treatment lag, and residual cognitive …

Objective This randomised, double‐blind, 12‐week study compared efficacy and tolerability
of flexible‐dose treatment with vortioxetine (10–20 mg/day) versus agomelatine (25–50 …

Purpose Anhedonia is a core symptom of major depressive disorder (MDD), which has
important functional consequences for the patient. This post hoc analysis investigated the …

Introduction Sexual dysfunction is common with serotonergic antidepressants, including
selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake …